- TWD4.10bn
- TWD3.55bn
- TWD306.31m
Annual income statement for Bonraybio Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 56.3 | 106 | 160 | 223 | 306 |
| Cost of Revenue | |||||
| Gross Profit | 39.6 | 80.6 | 120 | 175 | 239 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 94.8 | 113 | 138 | 162 | 206 |
| Operating Profit | -38.5 | -6.64 | 21.3 | 61 | 100 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.7 | 1.71 | 25.8 | 68.4 | 105 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -31.7 | 1.69 | 25.7 | 68.4 | 103 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -31.7 | 1.69 | 25.7 | 68.4 | 103 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.7 | 1.69 | 25.7 | 68.4 | 103 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.39 | 0.075 | 1.14 | 2.99 | 4.12 |
| Dividends per Share |